Preparation,, Quality Control and Biodistribution of 123I-MIBG

Mirzaei, Mohammad; Rajabifar, Saeed; Rahimi, Mohammad; Rasouli Garmarodi, Somayeh; Yousefnia, Hasan

doi:10.24200/nst.2025.1796.2106

Preparation,, Quality Control and Biodistribution of 123I-MIBG

Articles in Press

Document Type : Research Paper

Authors

Mohammad Mirzaei ¹

Saeed rajabifar ²

mohammad Rahimi ³

Somayeh Rasouli Garmarodi ²

Hasan Yousefnia ²

¹ Faculty Member

² Radiation Application Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-3486, Tehran – Iran

³ Pars Isotope Company, South Sheikh Bahaei Avenue, Tehran, Iran

https://doi.org/10.24200/nst.2025.1796.2106

Abstract

Iodine-123 radionuclide was produced through the bombardment of a xenon-124 gas target using protons with energy of 28.5 MeV in a cyclotron accelerator. After confirming the quality control procedures, the iodine-123 radionuclide with a purity of more than 99% and activity concentration of 8.47 ± 0.2 GBq/mL was used for labeling of MIBG chemical compound. The quality control of the labeled compound was performed using thin layer chromatography method by acetic acid:water:butanol (1:1:4) as the mobile phase. The quality control results indicated a radiochemical purity of more than 99% for the final product. The biodistribution of the radiolabeled compound was evaluated following the injection of 5.5–11.1 MBq of the 123I-MIBG radiopharmaceutical into rats, and the rats were dissected at various time intervals and imaging was performed. A comparative analysis of the biodistribution of free 123I and 123I-MIBG revealed that the radiolabeled compound exhibited a distinctly different biodistribution pattern compared to free 123I.

Keywords

123I-MIBG radiopharmaceutical

iodine-123 radioisotope

adrenal gland malignancies

biodistribution

Main Subjects